Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'remove_broken_stylesheets' not found or invalid function name in /home/v8dev/public_html/main/wp-includes/class-wp-hook.php on line 303
Skip to main content

Gluten-Free Living

Living Gluten-Free

Get Involved

Join the Effort

About the Foundation

Support the Foundation

10/24/2019

Cour Pharmaceuticals Announces Deal with Takeda for Celiac Treatment

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…

Continue Reading
2/28/2017

Partnership with ImmusanT to Promote Phase 2 Clinical Trial of Nexvax2®, A Promising Celiac Disease Treatment

ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease…

Continue Reading